含无机汞美白化妆品暴露致肾病综合征
该综述检索Medline、Embase等数据库至2019年3月,纳入14篇报告共30例经肾活检证实、有肾病范围蛋白尿且暴露于含汞美白产品的病例。30例均为亚洲女性,中位年龄34岁,暴露后1-60个月(中位5个月)发生肾病综合征,尿蛋白中位5.7 g/天;肾活检以微小病变型(67%)和膜性肾病(23%)为主。23例接受螯合剂(7例)或螯合剂联合激素(16例)治疗,9例蛋白尿缓解中位2个月,3例未用螯合剂者缓解≥12个月。结论认为除停用产品外,螯合治疗明确有指征,但二巯丙磺钠与二巯丁二酸的最佳剂量和策略尚未确定。
要点
- 30例均为亚洲女性,中位34岁,使用含无机汞美白产品后1-60个月(中位5个月)出现肾病综合征。
- 尿蛋白中位5.7 g/天,肾活检微小病变型占67%、膜性肾病占23%,其他汞中毒表现通常缺如。
- 24例尿汞为正常上限1.2-94.6倍(中位9.8倍),血汞6例正常、14例为上限1.1-10.9倍(中位3.5倍)。
- 螯合剂±激素治疗者蛋白尿缓解中位2个月(范围1-9个月),未用螯合剂者≥12个月。
- 作者认为除停用产品外,螯合治疗明确有指征;二巯丙磺钠与二巯丁二酸的最佳剂量和策略尚未确定。
适用人群与场景
- 有肾病范围蛋白尿、已行肾活检,且有含无机汞美白化妆品暴露史的患者。
- 纳入者需有肾病范围蛋白尿和肾活检资料;排除病史可疑、资料不完整、存在一种以上汞暴露来源、非肾病范围蛋白尿、接受草药治疗及重复文献者。
诊断标准与关键阈值
- 肾病范围蛋白尿:尿蛋白排泄3.2-20.7 g/天(中位5.7 g/天)。
- 尿汞升高:24例为正常上限1.2-94.6倍(中位9.8倍)。
- 血汞:6例正常,14例为正常上限1.1-10.9倍(中位3.5倍)。
- 蛋白尿缓解定义为尿蛋白<150 mg/天。
- 尿汞正常化定义为<35 nmol/天、<50 nmol/L或<5.0 nmol/mmol肌酐。
处置流程与药物剂量
- 停用含汞美白产品,并启动螯合治疗。
- 23例接受螯合剂(7例)或螯合剂联合激素(16例)治疗。
- 二巯丙磺钠(2,3-二巯基-1-丙磺酸)与二巯丁二酸的最佳剂量和治疗策略尚未确定。
研究设计与关键结果
- 综述纳入14篇报告共30例,均为亚洲女性,中位年龄34岁(多数18-52岁)。
- 肾病综合征发生于汞暴露后1-60个月(中位5个月)。
- 肾活检微小病变型占67%、膜性肾病占23%。
- 9例螯合剂(5例)或螯合剂联合激素(4例)治疗后蛋白尿缓解中位2个月(范围1-9个月);3例未用螯合剂者缓解≥12个月。
- 4例螯合剂(1例)或螯合剂联合激素(3例)治疗后尿汞正常化耗时9-16个月(均值约11个月)。
- 未用螯合剂者存在持续蛋白尿风险;自发性恢复罕见(1.5个月内)。
- 激素在汞所致肾病综合征中的辅助作用不明确。
证据类型、等级与局限
- 证据类型:系统检索的病例系列综述(14篇报告,30例)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对使用含汞美白产品后出现肾病综合征者,应停用产品并行螯合治疗;作者认为螯合治疗明确有指征。
- 二巯丙磺钠与二巯丁二酸的最佳剂量和治疗策略尚未确定。
- 激素的辅助作用不明确。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Introduction: Mercury has long been prohibited for use in skin-lightening agents, but such products are still widely available in many parts of the world.Objective: To evaluate the characteristics of subjects with nephrotic syndrome caused by exposures to skin-lightening products containing mercury and the impact of treatments with chelation agents and/or steroids on the time to achieve remission of proteinuria and normal urine mercury concentrations.Methods: We searched Medline and Embase (1971-31 March 2019), Google Scholar (2001-March 2019) and WanFang Data (1999-March 2019), using mercury, mercury poisoning, cosmetics, skin-lightening and nephrotic syndrome as search terms. Affected subjects must have had nephrotic range proteinuria and a renal biopsy performed. The searches revealed 46 citations, but 32 were excluded because of a doubtful history, incomplete data collection, more than one source of mercury exposures, non-nephrotic proteinuria, treatments by herbal medicines and duplicate articles. The 14 remaining reports describing 30 cases formed the basis of this review.Incidence and geographical origins: There was an obvious increase in the number of reports with more complete information from Asia (n = 13) and Europe (n = 1) during 2002-2006 (n = 3) and 2010-2017 (n = 11), involving 3 subjects in 2002-2006 and 27 subjects in 2010-2017.Characteristics of subjects: All 30 subjects were Asian females, mostly aged 18-52 years (median 34 years). Nephrotic syndrome occurred 1-60 months (median 5 months) after exposures to mercury. The proteinuria was heavy (urinary protein excretion 3.2-20.7 g/day, median 5.7 g/day). Other features of mercury toxicity were generally absent. Blood mercury concentrations were normal in 6 subjects and 1.1-10.9 times (median 3.5 times) the upper limit of normal in 14 subjects. Urine mercury concentrations were much higher in 24 subjects, at 1.2-94.6 times (median 9.8 times) the upper limit of normal. Renal biopsy typically revealed minimal change disease (67%) or membranous nephropathy (23%).Etiological importance of mercury: Several clinical observations strongly support the etiological importance of mercury, including a positive relationship between body mercury burden (24-h urine mercury excretion) and severity of proteinuria, the parallel (often proportional) reductions in body mercury burden and proteinuria after cessation of exposures and initiation of chelation therapy and the risk of persistent proteinuria in subjects not treated with chelating agents.Natural history and impact of specific treatments: Spontaneous recovery (within 1.5 months) of mercury-induced nephrotic syndrome was rare.Twenty-three subjects were treated with chelating agents (n = 7) or chelating agents plus steroids (n = 16). There was relatively clear information on the time to remission of proteinuria (urine protein <150 mg/day) in nine subjects following chelation therapy (n = 5) or chelation therapy plus steroids (n = 4) (median 2 months, range 1-9 months). In comparison, the time to remission was longer in three subjects not treated with chelation therapy (≥12 months). There were fewer reports with relatively clear information on the time to achieve normal urine mercury concentrations (<35 nmol/day, <50 nmol/L or <5.0 nmol/mmol creatinine). In four subjects with treatment by chelating agents (n = 1) or chelating agents plus steroids (n = 3), this took 9-16 months (mean ∼11 months). The adjunctive role of steroids in mercury-induced nephrotic syndrome was unclear.Conclusions: Repeated exposures to inorganic mercury in skin-lightening cosmetic products typically cause minimal change disease or membranous nephropathy, resulting in nephrotic syndrome. Apart from cessation of product use, chelation therapy is clearly indicated, in view of the etiological importance of mercury and the presence of increased body burden with target organ damage. The optimal dosages and treatment strategies for unithiol (2,3-dimercapto-1-propanesulfonic acid) and succimer (dimercaptosuccinic acid) have yet to be determined.
参考来源
- Chan TYK, Chan APL, Tang HL, et al. Nephrotic syndrome caused by exposures to skin-lightening cosmetic products containing inorganic mercury. Clin Toxicol (Phila). 2019. PMID: 31314603. doi:10.1080/15563650.2019.1639724
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。